for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. Approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.
Tablets
4297 EGP
for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. Approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.
Note: All the provided information about this drug does not substitute for consulting a doctor.